恩替卡韦联合舒肝解郁胶囊对肝硬化患者血清TGF-β_1 TIMP-1的影响

The affect of ETVand shu gan jieyu capsule on liver fibrosis patient serum TGFβ_1、TIMP-1

目的观察恩替卡韦联合疏肝解郁胶囊对乙肝肝硬化患者血清转化生长因子β1(TGF-β1)、金属蛋白酶组织抑制因子1(TIMP-1)的影响。方法选取住院乙肝早期肝硬化患者60例随机分为2组,每组30例,对照组在常规保肝、降酶等治疗基础上给予恩替卡韦治疗;治疗组在常规治疗基础上给予恩替卡韦及舒肝解郁胶囊治疗。治疗24周后,观察患者血清中丙氨酸转氨酶、透明质酸、Ⅳ型胶原、TGF-β1及TIMP-1的变化。结果经过24周的治疗,治疗组患者的丙氨酸转氨酶、透明质酸、Ⅳ型胶原、TGF-β1及TIMP-1的水平明显低于对照组。结论恩替卡韦联合疏肝解郁胶囊能够降低肝纤维化患者血清TGF-β1、TIMP-1的水平,具有抗纤维化的作用。

Objective To further assess the clinical antifibrotic efficacy of ETVand shu gan jieyu capsule on liver fibrosis patient serum TGFβ1、TIMP-1. Methods Total 60patients with HBV-related fibrosis was divided into two groups,30 patients per group,one group was cured by commn route medicine,the other group was cured by ETVand shu gan jieyu capsule,after 24weeks of treatment,to observe the change of patient serum ALT,HA,IVC,TGFβ1 and TIMP-1.Results After 24 weeks of treaments,the serum ALT、HA、IVC、TGFβ1、TIMP-1 level of the treament group are lower than that of the control group. Conclusion Liver fibrosis could be definitely reversed by ETVand shu gan jieyu capsule.